One consistent concern I hear about from my constituents in Oregon, and I have done 20 town halls so far this year, is the high cost of prescription drugs.

the fact is that there is going to be a lot of resistance if there is an apprehension that a patient can't get the medication he or she needs.

I'm amazed. I'm coming home, and they're there delivering the mail. They've been at it for 10 or 12 hours.

You made the case that if there are going to be some other--you're making the case for privatization.

I would just urge us to try to look for some way where we address this patient choice issue, because I know a lot of my colleagues have that concern. I have that concern.

I look forward to hearing from our witnesses, or our witness, on whether the current structure of how Part B drugs are reimbursed--can and should be modified to foster competition and to lower prices.

we are the only Government that I am aware of that really doesn't play an active role in trying to provide some pricing protection to benefit our taxpayers and consumers.

If we just have these costs go out of control, continue to go out of control, that cuts off access.

There is some argument that is always made by the pharma companies that if there is some pushback on their pricing power, that somehow means they are not going to innovate. I find that to be bogus because they are spending more on…

Due to a family emergency, I was unable to vote on Roll Call 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, and 167. I would include in the Record how I would have voted on each had I been present. rollcall 157: ``Aye'', rollcall 158…

If there is a withdrawal, presumably local actors would have to take over lots of functions.

It's a practical challenge. That's really what that says.

We can't wash our hands of the taxpayers' dollars just because we give it to the World Bank.

It's delightful to have you serving as our chair with your long experience on this committee.

Outside interference goes to the heart of our democracy. The most important challenge for our country is that we, the citizens of this country, make the decision on who is our President, who are our Senators, and who are our…

I thank the gentleman for yielding. Mr. Speaker, I don't know what is in the Mueller report and neither do you. The American people don't know what is in the Mueller report, but they want to know. And I want to know, as you do, and why…

The FOIA Improvement Act of 2016 requires agencies to establish procedures for identifying records of general interest that are appropriate for public disclosure.

It sounds like a rip-off, actually.

If you have specific suggestions about how any of these bills can be improved, I think that would be of great interest to our committee because we want to get this right.

So if you have specific suggestions about how any of these bills can be improved, I think that would be of great interest to our committee because we want to get this right.

I don't like litigation, all right? It just--it is the last resort.

Thank you, first of all, Madam Chair, for your leadership on this incredible issue of drug pricing.

How does it serve the public for the government agencies to subsidize these data bases?

I just want to mention again that the BLOCKING Act is a perfect example of us working in a bipartisan fashion.

We have got an opportunity, bipartisan, to finally tackle the rip-off pricing in the pharma system.